Review
doi: 10.2337/dc08-9018.
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Affiliations
- PMID: 18375431
- DOI: 10.2337/dc08-9018
Item in Clipboard
Review
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Diabetes Care.
2008 Apr.
No abstract available
Similar articles
-
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.J Am Coll Cardiol. 2008 Apr 15;51(15):1512-24. doi: 10.1016/j.jacc.2008.02.034. J Am Coll Cardiol. 2008. PMID: 18402913 Review. No abstract available.
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association: response to Skyler et al.Diabetes Care. 2009 Jul;32(7):e90-1; author reply e92-3. doi: 10.2337/dc09-9030. Diabetes Care. 2009. PMID: 19564469 No abstract available.
-
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.Diabetes Care. 2007 Jan;30(1):162-72. doi: 10.2337/dc07-9917. Diabetes Care. 2007. PMID: 17192355 Review.
-
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.J Am Coll Cardiol. 2009 Jan 20;53(3):298-304. doi: 10.1016/j.jacc.2008.10.008. J Am Coll Cardiol. 2009. PMID: 19147051 Review. No abstract available.
-
Cardiovascular disease in diabetes.Diabetes Care. 2008 Jun;31(6):1260-6. doi: 10.2337/dc08-zb06. Diabetes Care. 2008. PMID: 18509144 No abstract available.
Cited by
-
The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia.Cureus. 2024 Jul 27;16(7):e65521. doi: 10.7759/cureus.65521. eCollection 2024 Jul. Cureus. 2024. PMID: 39188504 Free PMC article.
-
Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.Arthritis Res Ther. 2024 Jun 24;26(1):123. doi: 10.1186/s13075-024-03352-3. Arthritis Res Ther. 2024. PMID: 38915065 Free PMC article. Clinical Trial.
-
Establishing Apolipoprotein-B and non-high-density-lipoprotein-C goals in Indian population: A Cross-sectional study.Indian Heart J. 2024 May-Jun;76(3):154-158. doi: 10.1016/j.ihj.2024.06.003. Epub 2024 Jun 12. Indian Heart J. 2024. PMID: 38871221 Free PMC article.
-
Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus.Diabetes Metab J. 2023 Nov;47(6):837-845. doi: 10.4093/dmj.2022.0217. Epub 2023 Aug 23. Diabetes Metab J. 2023. PMID: 37915183 Free PMC article.
-
Cardiometabolic Risk: Characteristics of the Intestinal Microbiome and the Role of Polyphenols.Int J Mol Sci. 2023 Sep 6;24(18):13757. doi: 10.3390/ijms241813757. Int J Mol Sci. 2023. PMID: 37762062 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
